Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1
Aimovig is specifically designed to stop migraine before it starts2,3
Play the Aimovig mechanism of action video below to see how it is believed to work in migraine.
Aimovig is the first licensed CGRP receptor antagonist in the UK, specifically designed to prevent migraine across the spectrum*1,4
Aimovig is 100% human and binds potently and selectively to the CGRP receptor, blocking its activation1
Aimovig injection training video
Watch this injection video for guidance on how to administer Aimovig.
CGRP, calcitonin gene related peptide; Ig, immunoglobulin.
- Aimovig® (erenumab) Summary of Product Characteristics.
- Aimovig Core Data Sheet v2.5.
- Garg S, et al. Anaesthesiology 2020;36(1):104–109.
- Bigal ME, et al. Headache 2013;53(8):1230–1244.